Skip to main content Back to Top
Advertisement

9/9/2016

Propranolol Hydrochloride Tablets

Products Affected - Description

    • Propranolol oral tablet, Major, 10 mg, unit-dose 100 count, NDC 00904-0411-61
    • Propranolol oral tablet, Mylan Institutional, 10 mg, unit-dose 100 count, NDC 51079-0277-20
    • Propranolol oral tablet, Mylan Institutional, 20 mg, unit-dose 100 count, NDC 51079-0278-20
    • Propranolol oral tablet, Mylan Institutional, 40 mg, unit-dose 100 count, NDC 51079-0279-20

Reason for the Shortage

    • Actavis has propranolol tablets available.
    • Heritage is not marketing propranolol tablets at this time.
    • Northstar discontinued all propranolol tablets in February 2015.
    • Mylan Institutional discontinued propranolol unit-dose tablets. The 10 mg tablets were discontinued in March 2013, the 20 mg tablets were discontinued in May 2014, and the 40 mg tablets were discontinued in January 2015.
    • Qualitest refuses to provide product availability as the company considers it proprietary information.
    • Teva divested all propranolol tablets to Global (Impax) Pharmaceuticals in August 2016.
    • Major discontinued propranolol tablets in early 2016.

Available Products

    • Propranolol oral tablet, Actavis, 10 mg, 100 count, NDC 00591-5554-01
    • Propranolol oral tablet, Actavis, 10 mg, 1000 count, NDC 00591-5554-10
    • Propranolol oral tablet, Actavis, 20 mg, 100 count, NDC 00591-5555-01
    • Propranolol oral tablet, Actavis, 20 mg, 1000 count, NDC 00591-5555-10
    • Propranolol oral tablet, Actavis, 40 mg, 100 count, NDC 00591-5556-01
    • Propranolol oral tablet, Actavis, 40 mg, 1000 count, NDC 00591-5556-10
    • Propranolol oral tablet, Actavis, 80 mg, 100 count, NDC 00591-5557-01
    • Propranolol oral tablet, Actavis, 80 mg, 500 count, NDC 00591-5557-05
    • Propranolol oral tablet, Global, 10 mg, 100 count, NDC 50111-0467-01
    • Propranolol oral tablet, Global, 10 mg, 1000 count, NDC 50111-0467-03
    • Propranolol oral tablet, Global, 20 mg, 100 count, NDC 50111-0468-01
    • Propranolol oral tablet, Global, 20 mg, 1000 count, NDC 50111-0468-03
    • Propranolol oral tablet, Global, 40 mg, 100 count, NDC 50111-0469-01
    • Propranolol oral tablet, Global, 40 mg, 1000 count, NDC 50111-0469-03
    • Propranolol oral tablet, Global, 60 mg, 100 count, NDC 50111-0470-01
    • Propranolol oral tablet, Global, 80 mg, 100 count, NDC 50111-0471-01
    • Propranolol oral tablet, Global, 80 mg, 500 count, NDC 50111-0471-02
    • Propranolol oral tablet, Mylan, 10 mg, 100 count, NDC 00378-0182-01
    • Propranolol oral tablet, Mylan, 10 mg, 1000 count, NDC 00378-0182-10
    • Propranolol oral tablet, Mylan, 20 mg, 100 count, NDC 00378-0183-01
    • Propranolol oral tablet, Mylan, 20 mg, 1000 count, NDC 00378-0183-10
    • Propranolol oral tablet, Mylan, 40 mg, 100 count, NDC 00378-0184-01
    • Propranolol oral tablet, Mylan, 40 mg, 1000 count, NDC 00378-0184-10
    • Propranolol oral tablet, Mylan, 60 mg, 100 count, NDC 00378-0187-01
    • Propranolol oral tablet, Mylan, 80 mg, 100 count, NDC 00378-0185-01
    • Propranolol oral tablet, Mylan, 80 mg, 500 count, NDC 00378-0185-05

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated September 9, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created July 2, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins